TIDMC4XD
RNS Number : 5486I
C4X Discovery Holdings PLC
27 November 2018
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
LifeArc and C4X Discovery join forces to develop small molecule
drug candidates active against a high value, novel oncology and
inflammation target
27 November 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that it has entered
into a discovery partnership with LifeArc(R), one of the UK's
leading medical research charities. C4XD and LifeArc will join
forces to progress medicinal chemistry efforts on a novel,
commercially attractive programme with applicability across
oncology and inflammation indications. The undisclosed target
originated from LifeArc's extensive partnerships in early-stage
academic research.
The partnership will combine leading drug discovery expertise
from both organisations, including application of C4XD's unique and
proprietary ligand-focussed conformational analysis platform,
Conformetrix, to LifeArc's extensive background and experience in
the programme. The aim is to develop oral, potent and selective
small molecule drug candidates against the undisclosed target
suitable for pre-clinical out-licensing to a clinical development
partner and, ultimately, to deliver a novel treatment in an area of
high unmet clinical need.
This discovery partnership adds a high value programme to C4XD's
portfolio. Furthermore, it demonstrates continued progress against
its stated strategy of utilising its cutting-edge drug discovery
engine, and establishing productive partnerships, to develop novel
small molecules against targets with high partnering interest.
Terms of the agreement are undisclosed.
Dr Clive Dix, CEO of C4X Discovery, said: "LifeArc is a
highly-respected medical charity with access to world-leading
academic research for conditions where there is a clear need for
new treatments coupled with deep experience in drug discovery. This
partnership not only demonstrates the potential of our Conformetrix
platform, it also highlights our strategic approach of accelerating
towards a diversified portfolio of pre-clinical assets for
out-licensing. We are delighted to be working with the LifeArc team
and look forward to a successful outcome and continuing to build on
our strategic relationship."
Dr Justin Bryans, LifeArc's Executive Director, Drug Discovery,
added: "LifeArc is delighted to partner with C4XD. Our new
partner's expertise in the rapid design and analysis of novel small
molecule therapeutics complements LifeArc's drug discovery
expertise. C4XD's focus on diseases with high unmet medical need is
entirely in line with our objective of ensuring that innovative
life sciences technologies progress along their development pathway
towards the patients who so desperately need them."
This announcement contains inside information for the purposes
of Article 7 of Regulatory (EU) No596/2014.
- Ends -
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer
+44 (0)7801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance) +44 (0)20 7886
2500
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709
5700
LifeArc
Glenn Mursell +44 (0) 207 391 2754
+44 (0) 7799 261 060
glenn.mursell@lifearc.org
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards the pre-clinical licensing
discussions. In selecting new targets and executing new drug
discovery programmes, C4X Discovery focuses on high-value disease
areas that are the subject of significant licensing activity and
will continue to also maximise value from opportunistic areas such
as addiction and diabetes. The Company recently signed a licensing
agreement with Indivior for a pre-clinical addiction programme
worth up to $294m.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
About LifeArc
LifeArc is a medical research charity with over 25 years'
experience in helping scientists and organisations turn their
research into effective diagnostics and treatments. LifeArc
collaborates with a wide range of life science charities and other
partners. In addition to portfolio review, IP protection,
technology transfer and licensing LifeArc also offers its partners
expertise in; early stage research funding, diagnostics
development, drug discovery, scientific scouting, campaigning, drug
discovery pipeline, in vitro diagnostics and antibody
engineering.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTFMMZMLVMGRZM
(END) Dow Jones Newswires
November 27, 2018 02:01 ET (07:01 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jun 2024 to Jul 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jul 2023 to Jul 2024